Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has reported a marked deterioration in its financial performance for the quarter ended December 2025, with key metrics such as revenue, profitability, and returns on capital contracting sharply. This downturn contrasts with the company’s historically robust growth trajectory and comes amid broader sectoral headwinds in Pharmaceuticals & Biotechnology.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Shree Ganesh Remedies Ltd., a pharmaceutical intermediates and fine chemicals manufacturer with a market capitalisation of ₹546.00 crores, reported net profit of ₹4.96 crores for Q2 FY26, marking a sequential improvement of 43.77% quarter-on-quarter but a concerning year-on-year decline of 22.62%. The Ankleshwar-based company's stock has been under severe pressure, trading at ₹424.00 and down 38.68% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers.

Shree Ganesh Remedies Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.415 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Shree Ganesh Remedies Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. Despite a strong long-term performance, recent weekly and monthly charts reveal deteriorating momentum, prompting a downgrade in its Mojo Grade from Strong Sell to Sell as of 5 January 2026.

Shree Ganesh Remedies Ltd has exhibited a subtle shift in price momentum, reflected in a transition from a bearish to a mildly bearish technical trend. Despite a 1.76% gain on 6 Jan 2026, the stock’s technical indicators present a complex picture, with some oscillators signalling mild bullishness while others remain bearish, underscoring a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 20 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Shree Ganesh Remedies touched a new 52-week low of Rs.418 today, marking a significant decline in its stock price amid broader market gains and sectoral outperformance. The pharmaceutical company’s shares have been trading below all key moving averages, reflecting persistent pressures over the past year.

Shree Ganesh Rem, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing financial and technical challenges. The stock’s recent assessment highlights shifts in key performance parameters, underscoring the company’s current position within a competitive and volatile market environment.

Shree Ganesh Remedies touched a fresh 52-week low of Rs.418.6 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past four consecutive sessions, culminating in an 8.09% return drop during this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Remedies has reached a new 52-week low of Rs.423, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have experienced a notable fall over recent sessions, reflecting a challenging period for the stock within the broader market context.

Shree Ganesh Rem, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial and technical developments. The stock’s assessment has shifted following a series of quarterly results and market performance indicators that have drawn attention to its current standing within the sector.

Shree Ganesh Remedies touched a fresh 52-week low of Rs.442.1 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial results and market dynamics that have influenced its valuation.

Shree Ganesh Remedies has hit a new 52-week low, reflecting a significant downturn in its stock performance amid broader market trends. The company has seen a notable decline in profitability, with profits before and after tax decreasing substantially. Despite these challenges, it maintains a low debt to EBITDA ratio.

Shree Ganesh Remedies has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company has reported negative results for the last three quarters, and its low Debt to EBITDA ratio indicates strong debt servicing ability, despite caution from institutional investors.

Shree Ganesh Remedies has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company has reported negative results for the last three quarters, and its stock continues to underperform in the market, indicating ongoing difficulties in regaining investor confidence.